Tests for Infertility | NYU Langone Health
At the NYU Langone Fertility Center, experts can perform a variety of tests to assess your fertility potential.
Tetralogy of Fallot in Children | NYU Langone Health
We use cookies and similar tools to give you the best website experience. By using our site, you accept ...
The (IRAD) International Registry for Acute Aortic Dissection
The purpose of this study is to collect information regarding your medical condition for a registry. The aim of the registry is to document a few important medical details of patients like you who were hospitalized for an acute aortic dissection. An aortic dissection is a serious condition in which a tear occurs in the inner layer of the body's main artery (aorta). Blood rushes through the tear, causing the inner and middle layers of the aorta to split (dissect). Based on the rarity of this disease and few guidelines regarding the most effective treatment for this disease, this registry aims to collect information from patients like you to study this disease. Patients from various hospitals in this country and in several other countries are being asked to participate. This information will help doctors understand more about acute aortic dissection. We believe this information will help to improve the treatment of patients like you in the future.
The Anti-Inflammatory Effects of Milk-Derived Extracellular Vesicles in Preterm Infant
The purpose of this study is to examine and compare Milk-Derived Extracellular Vesicles (EVs) in three types of milk: mothers' own milk, donor milk, and formula, and check how milk handling affects them. EVs are tiny particles in the milk.
The ConsideRAte study. A multipart exploratory study to evaluate splenic nerve stimulation in patients with rheumatoid arthritis.
The ConsideRAte study This study will evaluate the safety, tolerability, and effects ofstimulating the splenic neurovascular bundle (NVB) with an activeimplantable medical device system. The study will consist of 4 studyperiods, including a Randomized Control Trial period (Period 1), anOpen Label period (Period 2), a Treat-to-target period (Period 3), and aLong-term Follow-up period (Period 4). Participants with activerheumatoid arthritis (RA) will receive an implantable system and,following a recovery period of at least 28 days after implant of thesystem, will be randomly assigned at Day 1 (of Period 1) to receiveeither active stimulation or sham-stimulation via this system for 12weeks (84 days). Day 1 assessments will be used as baseline.Summary of IB Version 2:Version 1, 16 Dec 2020 Initial ReleaseVersion 2, 23 Jul 2021 Add preclinical testing supporting increase target stimulation dose increase from 15 mA to 20 mACover Page, Headers, Table of Contents Updated version, DatePage 3 Updated Sponsor signatory to Chief Medical OfficerSection 2.4 Removed previous target amplitudeSection 2.7 Added brief description of preclinical study (2nd GLP study); brief conclusionsSection 6.1 Added mention of new GLP study and brief resultsFigure 20 Corrected max dose amplitude in from 15 mA to 20 mASection 9.2 Added brief description of the new preclinical study (GAL1063)Section 9.4 Added more detailed description and results of the new preclinical study (GAL1063)Table numbers and section numbers Adjusted tables numbers and section numbers to account for the section added to describe the new GLP studySection 13.1.5 Updated results and figures from the new GLP study (GAL1063)Section 13.5.2 Updated estimated nerve recruitment rates and figure at the new target amplitude (20 mA) Section 14 Appendix II Added background rationale for GAL1063 study. Change to IB Version 3: Version 1, 16 Dec 2020 Initial ReleaseVersion 2, 23 Jul 2021 Add preclinical testing supporting increase target stimulation dose increase from 15 mA to 20 mACover Page, Headers, Table of Contents Updated version, DatePage 3 Updated Sponsor signatory to Chief Medical OfficerSection 2.4 Removed previous target amplitudeSection 2.7 Added brief description of preclinical study (2nd GLP study); brief conclusionsSection 6.1 Added mention of new GLP study and brief resultsFigure 20 Corrected max dose amplitude in from 15 mA to 20 mASection 9.2 Added brief description of the new preclinical study (GAL1063)Section 9.4 Added more detailed description and results of the new preclinical study (GAL1063)Table numbers and section numbers Adjusted tables numbers and section numbers to account for the section added to describe the new GLP studySection 13.1.5 Updated results and figures from the new GLP study (GAL1063)Section 13.5.2 Updated estimated nerve recruitment rates and figure at the new target amplitude (20 mA) Section 14 Appendix II Added background rationale for GAL1063 study. Version 3; 22 Oct 2021 Revised to include new validation packaging results, and updated tables from V&V testingCover Page, Headers, Table of Contents Updated version, DateSection 11.1 Updated Table 14 to describe the correction for Failed package testing as complete. Updated Table 15 & 16 to describe the design changes for the packages that were re-tested, and results.Section 11.1.1 Updated Table 18 V&V testing table to include the GAL1063 GLP study and PASS criteria
The DISCOVER INOCA Prospective Multi-center Registry - Determining the Cause of Coronary Vasomotor Disorders in Patients with Ischemia and No Obstructive Coronary Artery Disease
This is a prospective, multicenter, registry of stable patients with ischemia and no obstructive coronary artery disease (INOCA) evaluated by coronary angiography, intravascular imaging, and physiologic measurements obtained on the Coroventis Coroflow Cardiovascular System.The Coroventis Coroflow Cardiovascular System and PressureWire™ X Guidewire (Abbott, Abbott Park, IL) are a device combination consisting of a physiology wire with wireless transmitter (Wi-Box), CoroHub Receiver, and CoroFlow Software. The PressureWire™ X guidewire is a hydrophilic-coated wire with pressure and temperature sensors that is capable of measuring physiologic indices including fractional flow reserve (FFR), resting full cycle ratio (RFR), coronary flow reserve (CFR), and the index of microcirculatory resistance (IMR). The guidewire wirelessly transmits pressure and temperature data via the Wi-Box to the CoroHub Receiver and CoroFlow Software, which is a software interface designed to display pressure measurements, thermodilution curves, and physiologic indices. This registry will enroll 500 subjects at up to 10 sites in the United States that use the Abbott Coroventis Coroflow Cardiovascular System.The overall objective of this multi-center registry is to identify specific phenotypes of INOCA with both an anatomic evaluation (coronary angiography and intravascular imaging) and physiologic assessment with the Abbott Coroventis Coroflow Cardiovascular System, and to determine long-term outcomes. Specific goals include:- Describe the prevalence of the following INOCA phenotypes: coronary microvascular dysfunction (CMD), vasospastic angina, mixed CMD/vasospastic angina, other disorders of coronary physiology, and non-cardiac chest pain;- Characterize the burden of epicardial coronary artery atherosclerosis and myocardial bridging (MB) by angiography and intracoronary imaging (intravascular ultrasound or optical coherence tomography) in patients with INOCA;- Characterize the natural history and outcomes of patients with INOCA and determine variables associated with major adverse cardiovascular events
The first top-ranked med school with full-tuition scholarships | NYU Langone Health
At NYU Langone, our medical schools offer full-tuition scholarships to MD students, supporting our mission to teach.
The Global Paradise System US Post Approval Study (US GPS)
The objective of the Global GPS Registry is to evaluate the real-world use of the Paradise System as per approved labeling. In addition, US GPS will collect data in patient populations underrepresented within the RADIANCE clinical program. Information collected in this study will be analyzed to better understand the long-term safety and effectiveness of treatment with the Paradise System for patients with high blood pressure.
The GORE VBX FORWARD Clinical Study: A Comparison of the GORE VIABAHN VBX Balloon Expandable Endoprosthesis to Bare Metal Stenting for Patients with Complex Iliac Occlusive Disease
To demonstrate the superiority of the VBX Device for primary patency when compared to bare metal stenting in complex iliac occlusive disease.
The Hancock Jaffe Surgical Antireflux Venous Valve Endoprosthesis (SAVVE) Study Trial
To assess the safety and effectiveness of the Hancock Jaffe VenoValve for the treatment of patients with deep venous valvular insufficiencyA prospective, non-blinded, single-arm multi-center pivotal study of the Hancock Jaffe VenoValve. All patients will receive optimized care (e.g., appropriate medications, compression therapy) throughout the study.The study will be conducted in accordance with the 2020 Standard ISO 14155 (Clinical investigation of medical devices for human patients - Good clinical practice), and other regulatory and legal requirements.